Evidence map›Paper›PMID 34527523›Full record

ArticleCardiovascular diagnosis and therapy2021

Long term mortality and readmissions after transcatheter aortic valve replacement.

Mourad H Senussi, John Schindler, Ibrahim Sultan, Ahmad Masri, Forozan Navid, Dustin Kliner, Arman Kilic, Michael S Sharbaugh, Amr Barakat, Andrew D Althouse and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diagnosis and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mourad H SenussiHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
John SchindlerHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ibrahim SultanHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ahmad MasriHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Forozan NavidHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Dustin KlinerHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Arman KilicHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Michael S SharbaughHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Amr BarakatHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Andrew D AlthouseHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Joon S LeeHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Thomas G GleasonHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Suresh R MulukutlaHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReadmissions following transcatheter aortic valve replacement (TAVR) are common but detailed analysis of cardiac and non-cardiac inpatient readmissions beyond thirty days to different levels of care are limited.

methodsOur study population was 1,037 consecutive patients who underwent TAVR between 2011-2017 within a multi-hospital quaternary health system. A retrospective chart review was performed and readmissions were adjudicated and classified based on primary readmission diagnosis (cardiac versus noncardiac) and level of care [intensive care unit (ICU) admission

resultsOf the 1,017 patients who survived their index hospitalization, there were readmissions due to noncardiac causes in 350 (34.4%) and cardiac causes in 208 (20.5%) during a mean 1.96 years of follow-up. The most common non-cardiac causes of readmission were sepsis/infection (14.3%), gastrointestinal (8.3%), and respiratory (4.8%), whereas heart failure (14.0%) and arrhythmias (4.6%) were the most common cardiac causes of readmission. A total of 191 (18.8%) patients were readmitted to the ICU and 372 patients (36.6%) were non-ICU readmissions. The risk of a noncardiac readmission was highest in the period immediately following TAVR (~4.5% per month) with an early high hazard phase that gradually declined over months. However, the risk of cardiac readmission remained stable at ~1% per month throughout. TAVR patients that were readmitted for any cause had markedly increased mortality; this was especially true for patients readmitted to an ICU.

conclusionsIn TAVR patients who survived their index hospitalization, non-cardiac readmissions were more prevalent than cardiac. The risk of readmission and subsequent mortality was highest immediately post-procedure and declined thereafter. Readmission to ICU portends the highest risk of subsequent death in this cohort. Patient baseline co-morbidities are an important consideration for TAVR patients and play a significant role in readmissions and outcomes.

Indexed as

TAVR outcomesTAVR readmissionsTranscatheter aortic valve replacement (TAVR)

Identifiers

PMID34527523
PMCPMC8410501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.